Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. McMullen M, et al. Among authors: loembe b. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2. Int J Gynecol Cancer. 2020. PMID: 32878963 Free PMC article.
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Langenberg MHG, et al. Among authors: loembe b. Ann Oncol. 2011 Nov;22(11):2508-2515. doi: 10.1093/annonc/mdq767. Epub 2011 Mar 4. Ann Oncol. 2011. PMID: 21378200 Free article. Clinical Trial.
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A. Awada A, et al. Among authors: loembe ba. J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209247 Clinical Trial.